Kaléo wins $96m BARDA contract for 2-PAM nerve agent auto-injector
Kaléo has been awarded a $96.1 million base contract by the Biomedical Advanced Research and Development Authority (BARDA) to complete late-stage development, manufacturing validation, and initial procurement of a pralidoxime chloride (2-PAM) auto-injector intended to treat organophosphate poisoning, including nerve agent exposure. The Glen Allen, Virginia company said the award covers adult and certain paediatric populations, and marks a progression from earlier development work toward potential deployment as a national medical countermeasure.
The contract, issued under the Project BioShield Act, follows a separate BARDA award made to Kaléo in 2024 to support next-generation 2-PAM auto-injector development. If the government exercises all additional options attached to the current agreement, the total contract value could reach approximately $340.9 million, representing a meaningful expansion of Kaléo's collaboration with BARDA and the Administration for Strategic Preparedness and Response (ASPR).
The medical case for a ready-to-use antidote
Pralidoxime works by reactivating acetylcholinesterase, the nerve-signalling enzyme that organophosphate compounds, including military-grade nerve agents such as sarin and VX, inhibit rapidly and potentially fatally. Time to treatment is critical: symptoms can develop within minutes of exposure, and the therapeutic window for 2-PAM is narrow. A pre-filled auto-injector removes the need for healthcare or emergency-responder training in drawing up and administering the drug under field conditions, which is why the format is preferred for stockpile deployment.
Michael Wells, chief executive of Kaléo, said the contract would "enable Kaléo to develop and deliver critical medicines through a proven, highly reliable auto-injector platform designed to perform when every second matters." Kaléo's existing commercial portfolio, which includes the AUVI-Q epinephrine auto-injector, gives the company a manufacturing base and regulatory track record relevant to this programme.
Market and policy context
BARDA's medical countermeasure contracting sits within the broader Project BioShield framework, which Congress established to create a sustained procurement mechanism for chemical, biological, radiological and nuclear (CBRN) threats. The 2-PAM auto-injector programme complements the federal CHEMPACK initiative, which pre-positions nerve agent antidotes at locations across the United States to cut response times during a mass-casualty chemical incident.
Kaléo is not the only company with auto-injector expertise relevant to this space. Several established drug-device combination manufacturers, including those supplying atropine auto-injectors already held in national stockpiles, operate in the countermeasure segment. However, BARDA's willingness to extend a second, substantially larger contract to Kaléo suggests the agency regards the company's Aerio platform as sufficiently differentiated in terms of reliability and human factors engineering to justify continued sole-source development. Independent validation of those claims will come at FDA review, which the contract explicitly funds.
The broader countermeasure procurement environment has grown more active in recent years, with BARDA increasing CBRN-related awards as part of updated national security preparedness assessments. Kaléo's contract adds to a pipeline of late-stage medical countermeasure products that BARDA is advancing simultaneously across anthrax, smallpox and radiological threat categories. Investors in the private company will view the award as meaningful revenue visibility, given that government milestone payments and procurement off-take are funded through to regulatory approval.